First Trust Advisors
KRYS icon

First Trust Advisors’s Krystal Biotech KRYS Stock Holding History

First Trust Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121M Sell
324,900
-25,621
-7% -$7.66M 0.07% 336
2026
Q1 		$90.5M Buy
350,521
+105,245
+43% +$28M 0.06% 372
2025
Q4 		$60.5M Sell
245,276
-3,116
-1% -$656K 0.04% 489
2025
Q3 		$43.8M Buy
248,392
+26,022
+12% +$3.89M 0.03% 624
2025
Q2 		$30.6M Buy
222,370
+189,245
+571% +$27.8M 0.02% 760
2025
Q1 		$5.97M Buy
33,125
+9,956
+43% +$1.67M 0.01% 1233
2024
Q4 		$3.63M Sell
23,169
-16,242
-41% -$2.88M ﹤0.01% 1542
2024
Q3 		$7.17M Buy
+39,411
New +$7.6M 0.01% 1169

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First Trust Advisors's KRYS Position: Q2 2026 in Review

First Trust Advisors reduced its Krystal Biotech (KRYS) stake by 7.3% in Q2 2026, selling an estimated $7.66M and leaving 324,900 shares worth $121M. The position accounts for 0.07% of the portfolio, ranked #336.

First Trust Advisors first reported a position in KRYS in Q3 2024 and has held it in 8 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • First Trust Advisors held 324,900 shares of Krystal Biotech worth $121M as of Q2 2026.
  • First Trust Advisors sold 25,621 Krystal Biotech shares in Q2 2026, an estimated $7.66M.
  • Krystal Biotech made up 0.07% of First Trust Advisors's portfolio in Q2 2026, its #336 holding.
  • First Trust Advisors first reported a position in Krystal Biotech in Q3 2024 and has held it in 8 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.